| Literature DB >> 22683636 |
Hisashi Kawazoe1, Vladimir N Bilim, Andrey V Ugolkov, Kaori Yuuki, Sei Naito, Akira Nagaoka, Tomoyuki Kato, Yoshihiko Tomita.
Abstract
Sorafenib is a multikinase inhibitor approved for the systemic treatment of renal cell carcinoma (RCC). However, sorafenib treatment has a limited effect due to acquired chemoresistance of RCC. Previously, we identified glycogen synthase kinase-3 (GSK-3) as a new therapeutic target in RCC. Here, we observed that sorafenib inhibits proliferation and survival of RCC cells. Significantly, we revealed that sorafenib enhances GSK-3 activity in RCC cells, which could be a potential mechanism of acquired chemoresistance. We found that pharmacological inhibition of GSK-3 potentiates sorafenib antitumor effect in vitro and in vivo. Our results suggest that combining GSK-3 inhibitor and sorafenib might be a potential new therapeutic approach for RCC treatment.Entities:
Mesh：
Substances：
Year: 2012 PMID： 22683636 DOI： 10.1016/j.bbrc.2012.05.147
Source DB: PubMed Journal: Biochem Biophys Res Commun ISSN： 0006-291X Impact factor: 3.575